Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Standstill

<< Previous

Bullboard Posts

Next >>

Comment by Theknocker91on May 07, 2020 10:47am

127 Views

Post# 30997618

RE:Standstill

It's up to management at this point to prove themselves. This company has been mismanaged and wasteful for years, constantly behind schedule and not very transparent. GW pharma has basically the same drug and they're a multi billion dollar company now. I have hundreds of thousands of shares and I'm really hoping for this to be successful but you can't blame investors or potential partners to be wary, especially after that thankfully cancelled stero acquisition fiasco. Now we have to wait until financials are released HOPEFULLY by mid June before we hear anything about a potential partnership.

<< Previous

Bullboard Posts

Next >>

A junior copper-gold stock trading at a bargain of monumental proportions